Cc. Mok et al., ACUTE TRANSVERSE MYELOPATHY IN SYSTEMIC LUPUS-ERYTHEMATOSUS - CLINICAL PRESENTATION, TREATMENT, AND OUTCOME, Journal of rheumatology, 25(3), 1998, pp. 467-473
Objective. Acute transverse myelopathy (ATM) is a rare manifestation o
f systemic lupus erythematosus (SLE). The pathogenesis is unclear and
the optimal management strategy is uncertain because of the lack of co
ntrolled trials. In this study, the clinical presentation, autoantibod
y profile, treatment, and outcome of cases of ATM in our local SLE pop
ulation were retrospectively analyzed and compared with SLE controls.
Results. Ten cases of ATM were identified among 315 patients with SLE
studied, giving a prevalence of 3.2%. In 5 of the patients, ATM was th
e initial manifestation of SLE. The cervical cord was the most common
site of involvement (50%). Cerebrospinal fluid abnormalities were pres
ent in 63% of the patients, while magnetic resonance imaging (MRI) of
the spinal cord revealed abnormal T2 signals in 56%. Only one patient
had lupus nephritis. ATM was not associated with antiribosomal P or an
ti-extractable nuclear antigen (anti-ENA) antibodies. Positive dsDNA a
ntibody was present in 40% of the ATM cases, which was significantly l
ower than that of patients with active SLE without spinal cord disease
(75%; p = 0.04). No significant differences in the prevalence of anti
cardiolipin antibodies and lupus anticoagulant between the ATM and the
non-ATM group were observed. Only 3 patients with ATM showed hypocomp
lementemia or disease activity in other organs at the time of diagnosi
s, All the patients with ATM received corticosteroids, while 9 were gi
ven cytotoxic agents in addition. The response to treatment was variab
le -40% of patients had complete motor and sphincter recovery and 30%
had mild residual spasticity of the lower limbs. Conclusion. In our SL
E population, ATM was not associated with antiribosomal P, anti-ENA, o
r antiphospholipid antibodies. Systemic complement activation was not
evident in most patients during the acute phase of myelitis. Early agg
ressive therapy using a combination of corticosteroid and cytotoxic ag
ents is associated with a satisfactory outcome. Further prospective st
udy is needed to delineate the best treatment and its efficacy in the
prevention of relapses.